TRANSFORMING THE FUTURE

NASDAQ : TINY

FIRST. TRANSFORMATIVE. PROVEN.

SAFE HARBOR STATEMENT

This presentation may contain statements of a forward-looking nature relating to future events. Statements contained in this presentation that are forward-looking statements are intended to be made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company’s current beliefs, and a number of important factors could cause actual results to differ materially from those expressed herein.

Please see the Company’s Annual Report on Form 10-K, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company’s business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company’s actual results. Except as otherwise required by Federal securities laws, Harris & Harris Group, Inc. undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.

2

HARRIS & HARRIS GROUP

•  NASDAQ: TINY

•  NAV/Share: $3.85(1)

3

(1) NAV/Share as of September 30, 2014

CORPORATE MISSION

Harris & Harris Group Builds Transformative Companies

from Disruptive Science

4

COMPANY HIGHLIGHTS

•  30-Year History Building Companies

•  Holds Equity in Over 20 Transformational Companies

•  Value Not Yet Realized

•  Focused Strategy for Accelerated Growth

•  Strong Interdisciplinary Team

5

Invest

Build ValueReturn

BUSINESS MODEL

Evergreen Structure Facilitates Growth

•  NAV Growth•  Company Building•  Board Participation•  Partnerships

•  Early Stage•  BIOLOGY+

6

Liq

uid

Early-Stage,Active Involvement

Late-StagePassive Involvement

Illiq

uid

Investing in Disruptive Science

OUR COMPETITIVE POSITION

7

Public VC Firms

Public Holding Companies

Private VC Firms

OUR COMPETITIVE POSITION

8

Health Care Technology

BioTherapeutics&

Medical Devices

Health Care Services

Physics

Materials Science

Data & Analytics

Mathematics

Electronics

Engineering

Chemistry

WHY EARLY-STAGE

9

•  Opportunity to Generate Outsized Returns

•  Addressing Unmet Needs of S&P 500 Corporations

•  Limited Competition

•  Ability to Influence Company Strategy & Execution

Unique Skillset for Investing in BIOLOGY+

RECOGNIZED LEADERSHIP IN EARLY-STAGE

10

#1 Venture Capital Investor in High-Technology

As measured by GrantIQ’s SBIR Source in February 2014: www.sbirsource.com/sbir/investors

WE HAVE EXPERIENCE BUILDING COMPANIES

(Amgen, 2011) (NASDAQ:SZYM, 2011)

(CordenPharma, 2013)

(Asahi Kasei, 2011)

(Carl Zeiss, 2013)

Xradia Ancora

BioVex Crystal ISSolazyme

11

(Canon, 2014)

Molecular Imprints

GAME PLAN FOR ACCELERATED GROWTH

12

• Realize Value in Current Portfolio•  Invest in BIOLOGY+•  Partner for Resources & Expertise• Return Value to Shareholders

Note: Equity-focused portfolio companies, year of first investment and stage classifications as of September 30, 2014, not including 1) our publicly traded shares of Solazyme; 2) our rights to milestone payments associated with the acquisitions of BioVex Group, Nextreme Thermal Solutions and Molecular Imprints; and 3) portfolio companies currently in the process of being liquidated, have ceased or are in the process of ceasing operations and/or are seeking a sale of their assets, including Laser Light Engines, Ultora, SynGlyco and Cobalt.

PORTFOLIO BY STAGE

LATEEARLY MID

Mersana

Enumeral

ABS

Senova

AgBiome

EchoPixel

ProMuc

Nantero SiOnyx

OpGen

HZO

Bridgelux

Nanosys Cambrios

Adesto

PWA

Ensemble

Champions

D-Wave

Metabolon

BIOLOGY+

Other

Molecular Imprints

UberSeq

Accelerator

TARA Biosystems

13

METABOLON

•  Leader in Metabolomics: 3,000+ Studies, 60+ Patents, $96+ Million Cumulative Revenue

•  Diabetes Diagnostic Franchise

•  Partnerships With Leading Genomics Researchers and Corporations Including Leroy Hood, Craig Venter, Baylor Univ. and SynapDX

14

Actionable Diagnosis

•  Initial Investment: 2006 •  Capital Invested: $7.2 Million •  Voting Ownership: 10-15%•  Late Stage

Metabolomics Measure

Disease Status

DNA

RNA

Proteins

Disease/ Treatment

Mechanism

Biochemicals

Genetics Show Disease Risk

CHAMPIONS ONCOLOGY (OTC:CSBR)

•  Validated & Differentiated Platform for Personalized Medicine

•  Personalizing Treatments for Otherwise Untreatable Cancers

•  Accelerating Development of New Therapies for Cancers

15

>80% Positive Predictive Value

•  Initial Investment: 2011•  Capital Invested: $2.2 Million •  Ownership: ~2.5-5%•  Late Stage

TumorGraftTMMouse

Predictive Treatments

D-WAVE

•  Only Commercial Quantum Computer in the World

•  Demonstrating 10,000-100,000x Faster Problem Solving

•  Partnered with Lockheed, Google, and NASA

16

•  Initial Investment: 2006•  Capital Invested: $5.8 Million •  Voting Ownership: 2.5-5%•  Late Stage

ENUMERAL BIOMEDICAL (OTC:ENUM)

17

•  Spin-out of MIT/Harvard

•  Unique Platform that Leverages Human Cell Biology

•  Multiple Initial Engagements with Large Pharmaceutical Companies

•  Initial Investment: 2009•  Capital Invested: $5.6 million•  Ownership: 15-20%•  Early Stage

Proprietary Platform

NewDiagnostics

New Therapeutics

Recovery of Failed

Therapeutics

HZO

•  Provides Submersion Protection for Electronic Devices

•  Targeting Wearable, Defense, and Mobile Device Markets

•  Customers Include Top Brands and Manufacturers in Wearables

18

Submersion Protection

•  Initial Investment: 2011•  Capital Invested: $8.4 Million •  Voting Ownership: 15-20%•  Mid Stage

Interdisciplinary innovation is required to address these healthcare challenges.

HEALTHCARE TECHNOLOGY

SOLUTIONSBIOLOGY

Electronics

Physics

Materials Science

Chemistry

IT

Engineering

Mathematics

DISTINCTIVE APPROACH

19

BIOLOGY ENABLES H&H PORTFOLIO COMPANY

Engineering Single Cell Analysis

PhysicsNon-Invasive, High-Resolution Imaging

MathematicsHigh-Quality

Molecular Diagnostics

Material ScienceTargeted

Bio-CompatibleDrug Delivery

Electronics Personal Genomics

AnalyticsProtein Structure

Analysis

A DECADE OF BIOLOGY INVESTMENTS

20

Technology Platforms

CompanyBuilding

MarketAccess

Scale &Manufacturing

Corporate Partner

Corporate Partners are Highly Complementary

Technology Platforms

CompanyBuilding

MarketAccess

Scale

PARTNERING EARLY IS BENEFICIAL

21

PORTFOLIO PARTNERS

22

H&HPortfolio

Public Sector

Private Sector

Note: Includes corporate partnerships since 2002, which is when the first of the current Managing Directors joined the firm.

NIST

DOE

NSF

NIH

DARPA

ONR

SephoraCrucell

BOSCH

3M

Google

Celgene

syngenta

MicrosoftHealth Diagnostic Laboratory, Inc.

LIFE Technologies

NASA

Bristol Myers Squibb

Bunge

Chevron

Coherent

Dow

Genentech

Hitachi Chemical

Illumina

Intel

LG Innotek

Lockheed MartinMetter Toledo

Mitsui

Panasonic

Samsung

Sanofi-Aventix

SynapticsUnilever Tyco

Novartis

Boehringer Ingelheim

Oxford Biosciences

Pfizer

Corporations currently add value to Harris & Harris Group and our portfolio companies in multiple ways.

CURRENT EXAMPLE OF OUR PARTNERING STRATEGY

23

RETURNING VALUE FOR SHAREHOLDERS

24

Generate Meaningful Returns by

Increasing Net Asset Value (NAV) per Share

GROWTH IN AVERAGE OWNERSHIP

Notes: Average ownership data includes investment-weighted ownership percentages on a fully diluted basis as of September 30, 2014, for unrealized investments including investments in pending tranches of previously closed financings, as applicable. Many of our current portfolio companies may raise additional capital, and depending on many factors our ownership could increase or decrease in these companies as a result of these financings. The data for 2005-2008 does not include ownership in Ancora Pharmaceuticals Inc. If this investment was included, the investment-weighted average ownership would be approximately 16 percent. There is no guarantee that the projections of average future ownership will be achieved. Do not place undue reliance on such projections.

5%

9%

15%

20%+

0%

5%

10%

15%

20%

2001-2004 2005-2008 2009-2014 Goal

Ave

rage

Ow

ner

ship

25

STRONG INTERDISCIPLINARY TEAM

26

Doug Jamison Managing Director, CEO

Daniel Wolfe, PhDManaging Director, President

•  89 Years of Experience* •  35 Exits for $2.5 Billion**•  Domain Expertise

Alexei Andreev, PhDManaging Director, EVP

Misti Ushio, PhDManaging Director, CSO

Blake Stevens, PhDSenior Associate, VP

*Includes Investing and Industry experience** Total value of portfolio companies at time of exit without potential

future milestone payments since 2002, when first deal team member joined

COMPANY HIGHLIGHTS

•  30-Year History Building Companies

•  Holds Equity in Over 20 Transformational Companies

•  Value Not Yet Realized

•  Focused Strategy for Accelerated Growth

•  Strong Interdisciplinary Team

27

CORPORATE MISSION

Harris & Harris Group Builds Transformative Companies

from Disruptive Science

28

29